Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials
- 23 October 2003
- journal article
- Published by Elsevier in Protein Expression and Purification
- Vol. 33 (1) , 123-133
- https://doi.org/10.1016/j.pep.2003.09.003
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complexThe Journal of cell biology, 2003
- Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?Leukemia, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapiesCurrent Opinion in Hematology, 2003
- Mechanisms of Drug Resistance in AMLPublished by Springer Nature ,2002
- Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th centuryToxicon, 2001
- Molecular Characterization of Key Diphtheria Toxin:Receptor InteractionsBiochemical and Biophysical Research Communications, 2000
- Effect of Complete Remission on Survival in Patients With Acute Myelogenous Leukemia Receiving First Salvage TherapyBlood, 1999
- Long‐term survival in acute myeloid leukemiaCancer, 1997
- The crystal structure of diphtheria toxinNature, 1992